MDY Mdy Healthcare

RNS No 1609c
MEDISYS PLC
3rd November 1998



                                  MEDISYS PLC
                                       
                APPOINTMENT OF SENIOR MANAGEMENT FOR HYPOGUARD
                                       
Medisys PLC ("Medisys"), a leading provider of diagnostic, medical and safety
products, announces the appointments of Alan Dorling (39) as managing director
and Malcolm Luker (43) as director of business development at Hypoguard, its
diagnostics operating division.

Mr. Dorling, most recently with Wyeth UK as commercial director, brings 17
years of healthcare industry management experience to Hypoguard.  Dr. Luker,
previously international sales and marketing director, diagnostics division,
Genzyme, adds 14 years of business development experience both in the UK and
abroad.

At Wyeth, Mr. Dorling was responsible for operations of the SMA Nutrition
division, accounting for some #75 million in annual revenues.  Prior to Wyeth,
he was responsible for business development at Lederle Laboratories.  Earlier,
Mr. Dorling was head of Roche General Medical Products Division.

Dr. Luker was responsible for export development at Genzyme, which during his
tenure was awarded the Queen's Award for Export.  Prior to joining industry,
Dr. Luker was a genetic research scientist at University of Edinburgh.

"We are very pleased to be joined by two such experienced, capable executives,
who between them have more than 30 years in the healthcare and diagnostics
industries," said Kurt Amundson, chief operating officer of Medisys.  "With
new product licensing opportunities, strategic partnering and joint ventures
soon to be available to Hypoguard, the combined experience and skill sets of
Mr. Dorling and Dr. Luker will serve shareholders well."

In August, Medisys completed a #15 million convertible bond offering, led by
Nomura International.  Proceeds were used to complete the acquisition of
Lukens Medical Corporation, a Nasdaq-traded supplier of medical products.

"With the inclusion of Lukens, the group has grown from 100 employees to more
than 250," noted Amundson.  "We are currently in the process of integrating
the NIC companies into Lukens, to increase operating efficiencies.  Within the
next three months, the group will consist of the Hypoguard division and the
Lukens Medical Division."


Enquiries:

Kurt Amundson, Chief Operating Officer               Tel: 001 650 327 7900
Medisys PLC

David Yates / Sophie Pender-Cudlip                   Tel:  0171 457 2345
Gavin Anderson & Company


END

BOAKXFBBVFKLFKF

MDY Healthcare (LSE:MDY)
Historical Stock Chart
Von Jun 2024 bis Jul 2024

MDY Healthcare (LSE:MDY)
Historical Stock Chart
Von Jul 2023 bis Jul 2024